Gene · 1237
Papers2,300
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
241 to 260 of 2,300
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Female Sex Hormones Upregulate the Replication Activity of HIV-1 Sub-Subtype A6 and CRF02_AG but Not HIV-1 Subtype B. | Pathogens | 2023 | 37513727 | PubTator, text mining | PubMed |
| Single-cell analyses implicate ascites in remodeling the ecosystems of primary and metastatic tumors in ovarian cancer. | Nat Cancer | 2023 | 37488416 | PubTator, text mining | PubMed |
| Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell Carcinoma. | Cancer Res Commun | 2023 | 37484198 | PubTator, text mining | PubMed |
| Monocyte-endothelial cell interactions in vascular and tissue remodeling. | Front Immunol | 2023 | 37483594 | PubTator, text mining | PubMed |
| Tumors produce glucocorticoids by metabolite recycling, not synthesis, and activate Tregs to promote growth. | J Clin Invest | 2023 | 37471141 | PubTator, text mining | PubMed |
| Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition. | Oncoimmunology | 2023 | 37470057 | PubTator, text mining | PubMed |
| GHRL as a prognostic biomarker correlated with immune infiltrates and progression of precancerous lesions in gastric cancer. | Front Oncol | 2023 | 37469414 | PubTator, text mining | PubMed |
| Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer. | J Immunother Cancer | 2023 | 37463790 | PubTator, text mining | PubMed |
| Emerging roles of a chemoattractant receptor GPR15 and ligands in pathophysiology. | Front Immunol | 2023 | 37457732 | PubTator, text mining | PubMed |
| PGE2-EP2/EP4 signaling elicits mesoCAR T cell immunosuppression in pancreatic cancer. | Front Immunol | 2023 | 37457723 | PubTator, text mining | PubMed |
| Identification of immune-related target and prognostic biomarkers in PBMC of hepatocellular carcinoma. | BMC Gastroenterol | 2023 | 37438735 | PubTator, text mining | PubMed |
| Integrative analysis of single-cell embryo data reveals transcriptome signatures for the human pre-implantation inner cell mass. | Dev Biol | 2023 | 37437860 | PubTator, text mining | PubMed |
| Comprehensively analysis of immunophenotyping signature in triple-negative breast cancer patients based on machine learning. | Front Pharmacol | 2023 | 37426809 | PubTator, text mining | PubMed |
| S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells. | Mol Cancer Ther | 2023 | 37420296 | PubTator, text mining | PubMed |
| The emerging roles of SUMOylation in the tumor microenvironment and therapeutic implications. | Exp Hematol Oncol | 2023 | 37415251 | PubTator, text mining | PubMed |
| Clinical significance, tumor immune landscape and immunotherapy responses of ADAR in pan-cancer and its association with proliferation and metastasis of bladder cancer. | Aging (Albany NY) | 2023 | 37414093 | PubTator, text mining | PubMed |
| T cell receptor signaling strength establishes the chemotactic properties of effector CD8+ T cells that control tissue-residency. | Nat Commun | 2023 | 37402742 | PubTator, text mining | PubMed |
| The landscape of cancer rewired GPCR signaling axes. | bioRxiv | 2023 | 37398064 | PubTator, text mining | PubMed |
| Treg-based immunotherapy for antigen-specific immune suppression and stable tolerance induction: a perspective. | Immunother Adv | 2023 | 37397971 | PubTator, text mining | PubMed |
| Identification of DDIT4 as a potential prognostic marker associated with chemotherapeutic and immunotherapeutic response in triple-negative breast cancer. | World J Surg Oncol | 2023 | 37391802 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1237/papers?page=13